Filing Details
- Accession Number:
- 0001567619-20-018938
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-09 17:01:51
- Reporting Period:
- 2020-11-05
- Accepted Time:
- 2020-11-09 17:01:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1556270 | Jay Jonathan Mazelsky | One Idexx Drive Westbrook ME 04092 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-11-05 | 355 | $463.45 | 43,996 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 1,307 | $465.02 | 42,689 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 107 | $465.81 | 42,582 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 310 | $467.33 | 42,272 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 400 | $468.92 | 41,872 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 714 | $470.34 | 41,158 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 264 | $471.34 | 40,894 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 247 | $473.99 | 40,647 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 200 | $475.18 | 40,447 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 300 | $476.73 | 40,147 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 209 | $468.47 | 39,938 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 246 | $469.86 | 39,692 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 100 | $470.79 | 39,592 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 147 | $473.99 | 39,445 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 300 | $476.73 | 39,145 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-05 | 600 | $0.00 | 38,545 | No | 5 | G | Direct | |
| Common Stock | Acquisiton | 2020-11-06 | 1,612 | $62.00 | 40,157 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-11-06 | 1,256 | $79.54 | 41,413 | No | 4 | M | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 5 | G | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Incentive Stock Option (right-to-buy) | Disposition | 2020-11-06 | 1,612 | $0.00 | 1,612 | $62.00 |
| Common Stock | Incentive Stock Option (right-to-buy) | Disposition | 2020-11-06 | 1,256 | $0.00 | 1,256 | $79.54 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-02-13 | No | 4 | M | Direct | |
| 0 | 2025-02-13 | No | 4 | M | Direct |
Footnotes
- Includes 18 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2020.
- Represents the weighted average price of the shares sold ranging from a low of $463.195 to a high of $463.59 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $464.628 to a high of $465.55 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $465.79 to a high of $466.06 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $467.30 to a high of $468.29 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $468.796 to a high of $468.966 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $469.96 to a high of $470.62 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $471.17 to a high of $472.10 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $475.04 to a high of $475.33 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $468.04 to a high of $468.95 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $469.31 to a high of $470.25 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Grant of option to buy 806 shares of IDEXX Laboratories, Inc. common stock that vested on the fifth anniversary of the date of grant without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- Grant of option to buy 628 shares of IDEXX Laboratories, Inc. common stock that vested on the fifth anniversary of the date of grant without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- Not applicable.
Billionaire Hedge Funds
